GVHD remains a serious complication after allogeneic SCT. We describe 13 paediatric patients treated with daclizumab for refractory acute GVHD (aGVHD). After 30 days of daclizumab administration, all patients with cutaneous aGVHD reached complete response. Among patients with gastrointestinal disease, 50 and 30% had complete and partial response, respectively, whereas 11 and 55% of patients with hepatic aGVHD achieved CR and PR, respectively. Overall, complete (46%) and partial (46%) responses were demonstrated in 92% of our patients, whereas the remaining patients (8%) were nonresponders. No life-threatening infectious episodes were recorded within 100 days from transplant in this selected group of paediatric patients. Overall 46% of patients were alive at a median of 461 days from SCT, but 50% of them developed chronic GVHD. In our experience, daclizumab proved to be a useful and safe treatment for refractory and steroid-resistant/dependent aGVHD, in particular for cutaneous and low-moderate intestinal involvement.
Introduction
GVHD represents one of the most important causes of morbidity and mortality in patients who undergo allogeneic SCT. [1] [2] [3] [4] Patients who fail to respond to first-line steroid treatment have poor prognosis, and although various second-line treatments have been proposed, to date, no standard treatment has proven to be effective.
Daclizumab (Zenapax, Roche, Nutley, NJ, USA) (Dac) is a 144-kDa humanized Ig MoAb directed to the IL-2 receptor-a (CD25), which inhibits the binding between IL-2 and activated lymphocytes. In studies involving exclusively adults, or both adult and paediatric populations, [5] [6] [7] [8] [9] [10] Dac is reportedly safe when used in children as rejection prophylaxis after organ transplantation, 11, 12 and effective in the second-line treatment of refractory acute GVHD (aGVHD) and chronic GVHD (cGVHD).
We report our experience with Dac in children affected by refractory and steroid resistant-/dependent aGVHD.
Patients and methods
Between November 2002 and November 2006, 70 paediatric patients underwent allogeneic SCT at the G Gaslini Children's Research Institute (Genova, Italy). GVHD prophylaxis included CsA alone for allogeneic SCT from a related HLA identical donor, whereas CsA was administered with rabbit antithymocyte globulin and short-course MTX for allogeneic SCT from an unrelated donor. The overall grade and the clinical stage of the organ involvement of aGVHD and cGVHD were graded according to published criteria. 13 Cultures for bacteria and fungi, as well as a weekly DNA search (PCR method) for EBV, CMV, adenovirus and BK virus were performed on all patients. Standard measures for the prevention of infectious complications, including fluconazole as antifungal prophylaxis and acyclovir to prevent herpes-related infections, were adopted. All patients who developed CMV reactivation (detected by pp65 antigenemia associated to qualitative and quantitative PCR for CMV) underwent antiviral treatment. The therapeutic strategy for EBV reactivation and for the prevention of EBV post transplantation lymphoproliferative disease (EBV-PTLD) were based on the administration of a MoAb against CD20 þ lymphocytes (rituximab 375 mg/m 2 weekly) when the number of EBV copies 420 000/100 000 of PBMCs.
First-line treatment of patients who developed aGVHD included methylprednisolone at a dosage of 2 mg/kg/day.
Patients who did not show clinical improvement within 4-5 days after beginning steroid therapy were defined as 'steroid-resistant', whereas those who developed clinical signs of aGVHD recurrence at steroid tapering or within 4 weeks after discontinuation were defined as 'steroiddependent'.
Extracorporeal photophoresis (ECP) was administered with steroid therapy in patients showing steroid resistant-/ dependent aGVHD, whereas increased doses of methylprednisolone (5 mg/kg/day) were given to selected patients with severe aGVHD who did not respond to low doses of steroids.
In our experience, 13 out of 70 patients (18.5%) developed aGVHD who were refractory to low or high doses of steroids, either with or without ECP. The patients' characteristics are shown in Table 1 . Overall 99% of these patients had grade III or IV aGVHD. Of 13 patients, 12 showed cutaneous aGVHD, and grade was 4II in 10 of them; 10 of 13 children developed intestinal aGVHD (4grade II in 6 of 10), and 9 of 13 had hepatic aGVHD (4grade II in 4 of 9 patients). None of these children responded to low doses of methylprednisolone (2 mg/kg/ day); high doses of steroids (5 mg/kg/day) were given to five patients, and ECP was administered to 8 out of 13 patients.
Considering their refractory aGVHD, all these patients underwent Dac treatment, and all on-going therapies including steroids and ECP were continued.
Dac was administered a median of 32 days after SCT (range 14-94) at a dosage of 1 mg/kg i.v. over 60 min at days þ 1, þ 4, þ 8, þ 15 and þ 22 without pre-medication. All patients were treated in the ward. Twelve patients received only one cycle of Dac, whereas one patient underwent a second cycle within the first 100 days after SCT.
Quantification of CD25 þ lymphocytes was assayed before administering Dac therapy and then again at day þ 100.
Response to Dac was evaluated at day þ 30 after the first dose of Dac and again at day þ 100 after SCT. Overall response and organ involvement assessment were defined as complete response (CR) in the presence of complete resolution of cutaneous, hepatic and gastrointestinal aGVHD, whereas partial response (PR) was defined as a decrease of at least one organ stage and no worsening in other districts. Patients who needed further treatment or who died of aGVHD were considered nonresponders. Informed consent was signed by the parents or guardians of all the enrolled children.
Results
Clinical evaluation of patients was carried out at baseline, at þ 30 days after Dac and again at þ 100 days from SCT. No major side effects were observed during or after the administration of Dac among our patients.
At day þ 30 after Dac administration, all 12 patients affected by cutaneous aGVHD had CR.
Of 10 children, 5 (50%) and 3 (30%) with gastrointestinal aGVHD had CR and PR, respectively. The remaining two (20%), both of whom had grade IV aGVHD, were nonresponders.
Hepatic aGVHD was present in nine patients: one (11%) and five (55%) of them achieved CR and PR, respectively. The remaining three children did not respond to treatment; they had grade II, III and IV aGVHD, respectively. Table 2 shows the clinical response related to the various organs at day þ 30 from treatment.
As for overall outcome of aGVHD at day þ 30 from treatment, 6 (46%) out of 13 patients achieved CR, 6 (46%) obtained PR and one child (8%) was a nonresponder. Steroid treatment was tapered while ECP was continued in patients who achieved CR or PR after Dac.
At day þ 100 from SCT, 5 (45%) out of 11 evaluable children showed CR. Two children died before day þ 100 from SCT because of a relapse of the underlying disease and grade IV aGVHD, respectively. The remaining four (36%) and two (18%) patients were partial or nonresponders. Table 3 shows the overall outcome related to the grading of aGVHD at day þ 30 from treatment and at day þ 100 from SCT. Table 4 reports the second-line treatment at the beginning of Dac, the CD25 levels before and at a median of 18 days from treatment, the overall response and the follow-up of each child. Seven patients developed 12 infectious episodes within 100 days from SCT. They consisted of seven CMV reactivations at a median of 20 days from Dac treatment (range 7-44), two VZV reactivations at days þ 34 and þ 74, and one Staphylococcus aureus sepsis at day þ 23. An increase in the number of EBV-DNA copies was documented at days þ 9 and þ 13 in the remaining two patients, but only one of them required treatment with rituximab.
Of 13 patients, 6 (46%) are still alive at a median of 461 days from SCT (range 122-1073) and at a median of 419 days from treatment (range 79-1003). Four of them developed cGVHD (limited in two cases and extensive in two). The remaining two patients are alive without cGVHD. Seven (54%) children died at a median of 206 days from SCT (range 47-657) and at a median of 187 days from treatment (range 23-643). The causes of death were relapse in three cases, secondary malignancy in one, GVHD in two and sepsis in one.
Discussion
The pathophysiology of aGVHD includes the activation of donor-derived T cells by the recipient and the production of IL-2 and IFN-g. IL-2 controls and amplifies the allogeneic immune response leading to the activation of further T and natural killer cell responses, thereby priming macrophages to release tumour necrosis factor-a and causing further inflammation to damage the skin and gut.
Dac binds the T-cell IL-2 receptor-a, which leads to the downregulation of its activity. This T-cell inhibition proved to be effective when Dac was used in the rejection prophylaxis of patients undergoing solid organ transplant. 11, 12 Dac was also found to be effective as second-line treatment of steroid-resistant GVHD in a limited number of reports that mostly referred to adult populations. [5] [6] [7] [8] [9] [10] Response rates for aGVHD ranged between 29 and 68% in these series; however, data regarding the children who were included in these studies were not evaluable separately because they were not stratified by age. The only study on an exclusively paediatric population showed the safety and efficacy of Dac in treating both acute and chronic cutaneous GVHD.
14 However, the role that Dac may play in gastrointestinal or hepatic GVHD could not be assessed on account of the small number of cases.
Our experience confirms the safety of Dac also in children with refractory aGVHD, as reported in earlier studies. 15, 16 Thirty days after treatment and 100 days after SCT, 46 and 45% of patients had CR to daclizumab, respectively, whereas 46 and 36% of patients obtained PR. These results confirm the higher response rate that was observed earlier in a paediatric series as compared with the series involving exclusively adult populations. 5, 8, 9 As far as organ involvement is concerned, all of our patients with cutaneous aGVHD responded to therapy, regardless of the grade of the disease. This result is in agreement with previous series that demonstrated the efficacy of Dac on this district. Unlike the earlier published paediatric population, our patients were also evaluable for gastrointestinal and hepatic disease: intestinal involvement responded in 80% of cases and all of the nonresponders were affected with advanced-phase disease. This is in line with the evidence that Dac may be more effective in early stages of aGVHD. 9 The liver appears to be the least responsive organ, with only one patient achieving CR.
Messina et al. 17 observed CR of resistant cutaneous, hepatic and gastrointestinal aGVHD after ECP in 76, 75 and 60% of patients, respectively, although the most noticeable effect was reached after 8 weeks of treatment. This approach has become widespread in many Italian paediatric centres, although a standard approach has not been approved yet. In our opinion, the use of ECP remains the most valid therapy for the second-line treatment of aGVHD.
In this study, we suggest the possible use of Dac in a selected group of paediatric patients with refractory and/or steroid-resistant/dependent aGVHD, or in subjects with contraindications to ECP such as severe intestinal bleeding or critical clinical conditions. Dac was chosen because at the time of the study there were no other Table 2 Clinical response according to the grade of aGVHD in each organ at day +30 from treatment Grade I  1  1  0  0  1  1  0  0  3  1  2  0  Grade II  1  1  0  0  1  1  0  0  2  0  1  1  Grade III  6  6  0  0  2  2  0  0  3  0  2  1  Grade IV  4  4  0  0  6  1  3  2  1  0  0  1  Total  12 MoAbs with the same characteristics of manageability and safety. 18 As was observed in earlier reported series of patients undergoing second-line treatment for aGVHD, most of our patients also developed opportunistic infections after therapy with Dac, although no major life-threatening infectious episodes occurred. The heterogeneity of earlier administered immunosuppressive treatments and the limited number of patients make it difficult to define the role of Dac in the development of viral infections.
Another crucial point regarding the use of Dac that was reported in the other studies is the increased risk of relapse because of a theoretical reduction of the GVL effect, although this has never been shown in patients with refractory GVHD. In fact, the only randomized study showing disease-related reduced survival involved a population receiving Dac associated with steroids in the first-line treatment of GVHD. 15 Our relapse rate is in line with literature data, and involves three patients who received allogeneic HSCT for neuroblastoma, AML in second PR and ALL in second CR, respectively.
In conclusion, in our experience the use of Dac would appear to be a safe and efficient type of treatment for cutaneous aGVHD (every grade), for gastrointestinal aGVHD (grades I-III) and for mild (grade I) hepatic aGVHD. Hepatic and high-grade intestinal involvement appear to be less sensitive to this treatment. Nonetheless, the role that Dac may play in the risk of developing an infection or a relapse of the underlying disease still remains unclear. However, the risk of relapse should be carefully taken into consideration before using Dac, and very close monitoring of opportunistic infections should be adopted. Studies on larger groups of paediatric patients are still needed to define its role in the treatment of refractory aGVHD. Table 4 Overall aGVHD and involved organs; ongoing treatment at the beginning of Dac; CD25 levels before and after treatment; overall response at days +30 and +100 and follow-up of each child 
